Research article

Antimicrobial susceptibility and molecular characterization for some virulence factors of Proteus Mirabilis isolated from patients in Al-Qadisiyah Province, Iraq

Najlaa Abdallah D. Al-Oqaili1 Majed Kadim Al-Shebli2 Azhar N.H. Almousawi3

1. College of Biotechnology/University of Al-Qadisiyah, Iraq
2. College of Education/University of Al-Qadisiyah, Iraq
3. College of Pharmacy/University of Al-Qadisiyah, Iraq

Corresponding Author Email: najlaa67890@gmail.com
Co-Author Emails: Ardikdm79@gmail.com azalmousawi@yahoo.com

(Received 19/7/2017, Accepted 8/10/2017)

Abstract

Total of 64 Samples clinical isolates were collected from various sources included urine, ear external swab, wounds swab, burns swab, high cervical and endometrium cervical swab, which was taken from (in-patients) and (out-patients) in Maternal, and General Teaching Hospital in Al-Diwaniyah city during the period from 1/3/2015 till 30/9/2015. The resistance of bacterial isolates to 12 different antibiotics was tested and isolates showed different resistance to anti-β-lactam including penicillin and Amoxicillin/Clavulanic acid by (100%), cefotaxime by (86%), and Cephalexin by (90.62%), Imipenem by (18.75%), and Meropenem by (15.62%). Some of the virulence factors have been studied genetically (20 isolate), in terms of the genetic aspect, five genes were obtained for virulence factors and at varying rates, as the urease enzyme ureC, fimbriae formation mrpA, flagella flaA, hemolysin enzyme hpmA and biofilm formation luxS (60, 40, 100, 45, 55) %, respectively.

Keywords: Antimicrobial susceptibility test, virulence factors genes, PCR, proteus mirabilis.

Introduction

Proteus mirabilis is a common causative agent of the severe invasive diseases. This microorganism expresses several virulence factors. P.mirabilis can expresses adhesins, flagella, and toxins. Proteus is a gram-negative bacteria associating to the Enterobacteriaceae family. Which is distinct from other species by swarming in the surface of agar (23). Proteus is a broad distribution in the environment that puts up a portion of the normal flora in a gastrointestinal tract of the human. It is ranked third in a cause of hospital-acquired infections (42). The opportunistic human pathogens represented by three species: P.vulgaris, P.mirabilis, and P.penneri (21). It is an important source of hospital-acquired infections (17). P.mirabilis the main cause of urinary tract infections (31,33,37,12), P.mirabilis is a common cause of urinary tract infection, most existing in patients with indwelling catheters and urinary tract structural abnormalities (3), respiratory tract and wounds infections (38), burns and digestive tract infections (44), Ear infection and Otitis media (7). P.mirabilis has a wide arrange of cell-associated factors, it can secreted a lot of factors, some of these factors have been closely rlated with disease producing potential called virulence factors (16, 39), such as swarming, fimbriae, urease, hemolysin, protease and Lipopolysaccharides (LPS)(41). This pathogen have develope several pathogenic factors including which listed above which enable them to colonize, survive and grow in the host organism (16, 40).
Materials and Methods

Ethical approval
The Animal Ethical Committee of Veterinary Medicine College, University of Al-Qadisiyah, Iraq, has approved the present study under permission No: 381.

Specimens’ collection
Different samples such as urine, wound swab, burn swab, high cervical, endometrium cervical and ear external swab, which was taken from (in-patients) and (out-patients) after taken the approval of the patient’s in Maternal and General Teaching Hospital in Al-Diwaniyah city during the period from 1/3/2015 till 30/9/2015. The collection process has been conducted according to (26).

Identification of Bacterial Isolates
The isolates were identified according to (18) by using traditional microscopic examination (Gram’s stain), colony morphological features on MacConkey agar and blood agar, and standard biochemical tests.

DNA extraction
The total genomic DNA of the *P. mirabilis* was isolated using the DNA extraction and purification kit (Geneaid, USA) according to the manufacturer instructions. DNA preparations were then analyzed by electrophoresis in 1.5% agarose gel.

Polymerase chain reaction
Polymerase chain reaction was used to amplify the entire sequences of the genes studied in this research. The specific primers (Bioneer, Korea) used for the amplification of these genes (45) were shown in (table 1).

Agarose gel electrophoresis
The products were separated in 1.5% agarose gel in TBE buffer (pH 8), stained with ethidium bromide, and photographed in ultraviolet light (14). The electrophoresis result noticed by using gel documentation system.

Detection of the virulence factors of *P. mirabilis*
1-Hemolysin production
2-Urease production
3-Biofilm formation
4-Detecting flagella
5-Detecting fimbriae

Table (1): The primer of some virulence factors genes in this study

| Primer                  | Sequence                   | Amplicon |
|-------------------------|----------------------------|----------|
| Urease ureC             | CAAGCCCAAGAGGTCTCGT        | 517bp    |
|                         | CAAGATGCTGGTCCACGGTA       |          |
| Fimbriae mrpA           | CCGGTCTGTCTTTAGCTGCA       | 359bp    |
|                         | GTTTTGCACAGCACTTGGG        |          |
| Flagella flaA           | ATCAATGCGCTGCGACACT        | 445bp    |
|                         | TGAAGTACCGGTTTTGCA         |          |
| Hemolysin hpmA          | ACGTTCTAACTGCATGGCA        | 270bp    |
|                         | ACAAAAGCACCTTGGTCC         |          |
| Biofilm formation LuxS  | ACGTATGTCTGCACCTCG         | 290bp    |
|                         | CCATAGCTGGCTTCCATGCA       |          |

Antimicrobial susceptibility test (AST)
Determination of antimicrobial agents susceptibility by disk diffusion method (35), Which was gotten from BDH London, UK, which was: penicillin (P), augmentin (AUG), gentamycin (GM), cefotaxime (CTX), cephalaxin (CL), amikacin (AK), imipenem (IMP), Meropenem (MEM), Tobramycin (TOB), Kanamycin (K), Netilmicin (NET) and Streptomycin (S). The inoculum were prepared by growing of *Proteus mirabilis* on dispersed agar plates, then the colonies grow in the plate transferred by loop into a test tube filled with 3 ml of normal saline. The suspensions density was adapted to 0.5 McFarland standards. The plate surface of Muller-Hinton agar (Himedia India) was inoculated with bacteria by a sterile swab. The swab was soaked into the suspension and pressed into the side of the test tube to discard exuberance fluid, then inoculate the Muller-Hinton agar by streaking method. Antibiotic discs were applied to the inoculated agar and incubated
at 37°C overnight. The diameter of zone of growth - inhibition observed was measured and compared to the chart of National Committee for Clinical Laboratory Standards (NCCLS).

**Results**

Sixty four isolates were identified as *P. mirabilis* consisted of 32 isolates (12.8%) obtained from urine, 17 isolates (9.18%) obtained from external ear, 3 isolates (7.5%) obtained from wounds, 4 isolates (4.7%) obtained from burns and 8 isolates (8.88%) obtained from high cervical and endometrium cervical (Table 2).

Table (2): Distribution of *P. mirabilis* among various clinical sources

| Type of samples                  | No. of samples (%) |
|----------------------------------|--------------------|
| Urine                            | 32 (12.8)          |
| External ear                     | 17 (9.18)          |
| Wounds                           | 3 (7.5)            |
| Burns                            | 4 (4.7)            |
| High cervical and endometrium cervical | 8 (8.88) |
| **Total**                        | 64 (9.84)          |

**Susceptibility of *P. mirabilis* isolates to different antimicrobial agents**

(Table3) shows a higher percentage of resistance to both Penicillin and amoxicillin with clavulanic acid (100%), while, the lowest resistance with imipenem and Meropenem (18.75% and 15.62 %), respectively.

**Virulence factors of *P. mirabilis***

The results of the PCR for 20 *P. mirabilis* isolates showed that higher percentage of gene *flaA* (100%), while, the lowest percentage of gene *mrpA* (40%) (Table 4). Figure (1, 2, 3, 4, 5) shows that PCR amplified production for 20 *P. mirabilis*.

### Table (3): Percentage (%) of antimicrobial resistance and sensitivity of *P. mirabilis*

| Antibiotics | Resistance isolates | Sensitive isolates |
|-------------|---------------------|--------------------|
|             | No. (%)             | No. (%)            |
| Penicillin  | 64 100              | 0 0                |
| Augmentin   | 64 100              | 0 0                |
| Cefotaxime  | 55 86               | 9 14.06            |
| Cephalexin  | 58 90.62            | 6 9.37             |
| Imipenem    | 12 18.75            | 52 81.25           |
| Meropenem   | 10 15.62            | 54 84.37           |
| Gentamycin  | 35 54.68            | 29 45.31           |
| Amikacin    | 20 31.25            | 44 68.75           |
| Tobramycin  | 49 76.56            | 15 23.43           |
| Kanamycin   | 52 81.25            | 12 18.75           |
| Streptomycin| 55 85.93            | 9 14.06            |
| Netlimicin  | 52 81.25            | 12 18.75           |

### Table (4): The numbers and percentages of the genes of Virulence factors for 20 *P. mirabilis* isolate

| Virulence factors genes | No. *P. mirabilis* isolates | (%) |
|-------------------------|-----------------------------|-----|
| *ureC*                  | 12                          | 60  |
| *mrpA*                  | 8                           | 40  |
| *flaA*                  | 20                          | 100 |
| *hpmA*                  | 9                           | 45  |
| *luxS*                  | 11                          | 55  |

Figure (1): PCR amplified production of *P. mirabilis* isolates using *ureC* gene primers. M: marker ladder (100-2000 bp). Lanes 1-12 the isolates showed positive results with *ureC* gene, (80mA and 100V) for one hour.
Figure (2): PCR amplified production of P. mirabilis isolates using *mrpA* gene primers. M: marker ladder (100-2000 bp). Lanes 1-8 the isolates showed positive results with *mrpA* gene, (80mA and 100V) for one hour.

Figure (3): PCR amplified production of *P. mirabilis* isolates using *flaA* gene primers. M: marker ladder (100-2000 bp). Lanes 1-20 the isolates showed positive results with *flaA* gene, (80mA and 100V) for one hour.

Figure (4): PCR amplified production of *P. mirabilis* isolates using *hpmA* gene primers. M: marker ladder (100-2000 bp). Lanes 1-9 the isolates showed positive results with *hpmA* gene, (80mA and 100V) for one hour.

Figure (5): PCR amplified production from extracted DNA of *P. mirabilis* isolates using *luxS* gene primers. M: marker ladder (100-2000 bp). Lanes 1-11 the isolates showed positive results with *luxS* gene, (80mA and 100V) for one hour.

**Discussion**

**Isolation and identification**

Sixty four isolates were identified as *P. mirabilis* consisted of 32 isolates (12.8%) obtained from urine, 17 isolates (9.18%) obtained from external ear, 3 isolates (7.5%) obtained from wounds, 4 isolates (4.7%) obtained from burns and 8 isolates (8.88%) obtained from high cervical and endometrium cervical. We analyzed resistance to 12 antibiotics belonging to two groups: beta-lactams and aminoglycosides all isolates showed microbiological resistance Penicillin, amoxicillin with clavulanic acid (100%), this result agrees with similar studies both of (10,8) Cefotaxime (86%), this result agrees with (2) about (83%), but this current result not agrees with (4) about (100%), also Cephalexin (90.62%) this result agrees with (10) about (80%), but this current result agrees with (8) about (42.85%). As for antibiotic aminoglycosides Gentamycin about (54.68%) this result agrees with (6) about (50%) but not agrees with (20) about (33%), also Amikacin (31.25%) this result agrees with (11) about (38.4%) but this current result not agrees with (25,6) about (1.6,5%), respectively. Tobramycin (76.56%) this result agrees with (5) about (81%) but this current result not agrees with (47) about (33.3%). also antibiotics Kanamycin, Streptomycin and Net-l-imicin about (81.25, 85.93, 81.25)% respectively.

**Virulence factors of *P. mirabilis***

The genotypic characters were tested for 20 *P. mirabilis* isolates in this study in order for detection of the virulence factors. The
results of the PCR for the isolates of *P. mirabilis* showed that (60%) isolates were positive for the presence of *ureC* gene, this result not agrees with (43) value *ureC* gene about (100%). Urease is one of the most important factors in *P. mirabilis* pathogenesis. In vitro (on basic urea agar), urease hydrolyzing urea to alkaline ammonia and carbon dioxide, thereby increasing the pH and will be changing the color of phenol red indicator to pink (19). However, in vivo (human body) this enzyme catalyzes the formation of kidney and bladder stones or to encrust or obstruct indwelling urinary (16).

In the current study found *mrpA* gene about (40%), this result agrees with (1) were value *mrpA* gene (35%), but current study not agrees with (28) were value gene (8%). Basic studies showed that serum from mice infected was reacted firmly to MR/P fimbrial preparations, which revealed that these fimbriae are expressed in vivo (32). MR/P fimbriae expression shown to be extremely induced through infection (24). The results of this study revealed that all *P. mirabilis* isolates (100%) possessed *flaA* gene, this finding is in agreement with other researches (29) and (9) that conducted in Iraq. They reported the presence of *flaA* gene in *Proteus* isolates (100%, 86.66%) respectively. While (13) found that (100%) of *P. mirabilis* isolates were carrying *Flil* gene which encodes for the flagellar basal body protein. In this study the presence of the *hpmA* gene was responsible for hemolycin about (45%), this result agrees with (46) about (46.7%), while not agrees with (8) about (100%). Finally in current study the presence of the *luxS* gene was responsible for biofilm formation about (55%), this result agrees with (1) who found value *luxS* gene about (47%).

**References**

1- Abbas KF, Al-Khafaji JK, Al-Shukri MS. Molecular Detection of some Virulence Genes in *Proteus mirabilis* Isolation from Hilla province. International J. of research studies in Biosciences (IJRSB), (2015); Vol.3(10), pp: 85-89.
2- Abdulghani ST. The outcome of the Misuse of 3rd Generation Cephalosporins In Fullujah City, West of Iraq. Al-Anbar Med. J., (2012); Vol. 10(2), pp: 46-50.
3- Adegbola RA, Old DC, Senior BW. The adhesins and fimbriae of *Proteus mirabilis* strains associated with high and low affinity for the urinary tract. J. Med. Microbiol. (1983); 16:427-431.
4- Al-Autbi DAK. Bacteriological study of some species of *Enterobacteriaceae* isolated from Hospital birth rooms in Baquba city. Thesis. (2013); Diyala University.
5- Al-Azawy AN, Al-Taai HRR, Al-Rajab IAM. Biological study of *Proteus mirabilis* isolated from different clinical sources in AL-Mqidadia city. Diyala J. for pure sci., (2015); Vol.11 (2), pp: 42-60. 6-Al-Bassam WW, Al-Kazaz A. The isolation and Characterization of *Proteus mirabilis* from different clinical Samples. J. of Biotechnology Research center (2013); Vol.7 (2).
7- Al-Bayati NS. Bacteriological and epidemiological study of chronic superlative otitis media among primary school children in tikrit city. M.Sc. Thesis, (2001); College of Medicine, Tikrit University.
8- Ali HH. Molecular study of some virulence factors of *Proteus mirabilis* isolated from urinary tract infection in Al-Qadisiyah province. Thesis, (2015); College of Sciences, University of Al-Qadisiyah.
9- Ali HH, Yousif MG. Detection of some virulence factors genes of *Proteus mirabilis* that isolated from urinary tract infection. Research article. Inter. J. of Adv. Res. 3: 2411-2012.
10- Al-jenahi MRA. Genetic study on isolated *proteus mirabilis* from urinary tract infection in children. Thesis, (2013); College of Education, Al-Qadisiya University.
11- Bahashwan SA, El-Shafey HM. Antimicrobial resistance patterns of Proteus Isolates from Clinical Specimens. European Sci. J., (2013); Vol.9 (27). Taibah University, Al Madinah Al Munawara.
12- Baldo C, Rocha SPD. Virulence Factors of Uropathogenic *Proteus Mirabilis* - A Mini Review. Inter. J. of Scient. and Technol. Res. (2014);3: 24-27.
13- Barbour EK, Hajj ZG, Hamadeh S, Shaib HA, Farran MT, Araj G, Faroon O, Barbour KE, Jirjis F, Azhar E, Kumasoni T, Harakeh S. Comparison of phenotypic and virulence genes characteristics in human and chicken isolates of *Proteus mirabilis*. Pathogens and Global Health, (2012); 106 (6):352-357.
14- Bartlett JMS, Stirling D (1998). PCR Protocols: Methods in Molecular Biology. 2nd. Humana Press Inc. Totowa. NJ.
15-Coker C, Poore CA, Li X, Mobley HLT. Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect. (2000); 2:1497-1505.
16-Filimon R, Iacob E. Incidence of nosocomial infection at the recovery clinic of Iasi hospital in 2004-2005. Rev. Med. Chir. Soc. Med. Iasi. (2007); 111(1): 255-257.
17-Forbes BA, Sahm DF, Weissfeld AS. Bailey and Scott's Diagnostic Microbiology. 12th ed. Missouri. Mosby Co.: (2007);323-333.
18-Friedrich AW, Koch R, Bielaszewska M, Zhang W, Karch H, Mathys W. Distribution of the Urease gene cluster among urea activity of enterohemorrhagic Escherichia coli OH157 isolated from humans. J. of Clin. Micr. (2005); 43(2):546-550.
19-Gangoue-Pieboji J, Koulla-Shiro S, Ngassam P et al. Antimicrobial activity against gram-negative bacilli from Yaounde Central Hospital, Cameroon. Afr. Health Sci., Vol. 6(4), (2006); pp: 232-235.
20-Guentzel MN (1996). Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus. In: Barron's Medical Microbiology (Barron 's et al., eds.) (4th ed.). Univ of Texas Medical Branch.
21-Himpsl SD, Lockatell CV, Hebel JR, Johnson DE, Mobley HL. Identification of virulence determinants in uropathogenic Proteus mirabilis using signaturetaggedmutagenesys. J. Med. Microbiol. (2008); 57:1068-1078.
22-Jacobsen SM, Stickler DJ, Mobley HLT, ME, Shirliff. Complicated Catheter-Associated Urinary Tract Infections Due to Escherichia coli and Proteus mirabilis. Clinical Microbiology Reviews, (2008); 21 (1): 26-59.
23-Li X, Lockatell CV, Johnson DE, Mobley HL. Identification of Mrpl as the sole recombinasin that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic Proteus mirabilis. Mol. Microbiol. (2002); 45:865-874.
24-Luzzaro FG, Lombardi M, Perlli R, Belloni G, Amicosante, A Toniolo (2001). Antimicrobial susceptibility testing and ESBL production in clinical isolates of Proteus mirabilis: An evaluation with the phoenix™ automated microbiology system. Presented at the 10 1st General Meeting of the Amer. Soci. For Microbiology.
25-MacFaddin JF (2000). Biochemical tests for identification of medical bacteria. 3rd ed.Lippincott Williams and Wilkins, USA.
26-Manos J, Belas R. The genera Proteus, Providencia, and Morganella. In The prokaryotes. Vol. 6. 3rd ed. Edited by Dworkin, Springer, New York. (2006); pp. 245-269.
27-Mohammed GJ (2014). Phenotyping and molecular characterization of proteus vulgaris isolated from patients with urinary tract infections. Ph. D. Thesis, College of Medicine, Babylon University.
28-Morgenstein RM (2006). Proteus mirabilis swarming O-antigen, surface sensing, and the Rcs system. Microbiology and Molecular Genetics.
29-Naber KG, Schito GC, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical 1702 aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for 1703 empiric therapy. Eur. Urol., (2008); 54 (12): 1164-1175.
30-Nielubowicz GR, Mobley HLT Host-pathogen interactions in urinarytract infection. Nat. Rev. Urol. (2010); 7(8): 430-441.
31-O'May GA, Jacobsen SM, Stickler DJ, Mobley HLT, Shirliff ME. Complicated urinary tract infections due to catheters: The Role of Biofilms in Device-Related Infections. Book. (2008); 7142- Chap. 6.
32-Pearson MM, Sebahia M, Churcher C, Quail MA, Seshasayee AS, Luscombe NM, Abdellah Z et al. Complete genome sequence of uropathogenic Proteus mirabilis, a master of both adherence and motility. J.Bacteriol. (2008); 190(11): 4027- 4037.
33-Pellegrino R, Scavone P, Umpiřeřez A, Maskell DJ, Zunino P. Proteus mirabilis uropathelial cell adhesion (UCA) fimbria plays a role in the colonization of the urinary tract, Pathogens and Disease, (2013); 67:104-107.
34-Ranjbar-Omid M, Arzanlu M, Amani M, Al-Hashem SKS, Mozafari NA, Doghareh HP. Allicin from garlic inhibits the biofilm formation and urease activity of Proteus mirabilis in vitro. FEMS. Microbiol. Letters, (2015);362 Issue 9.
35-Rozalski A, Torzewska A, Moryl M, Kwil I, Maszewska A, Ostrowska K, et al. Proteus sp.- an opportunistic bacterial pathogen -classification, swarming growth, clinical significance and virulence factors. Folia Biologica. et. Oecologica. (2012); 8:1-17.
36-Stamm WE (1999). Urinary Tract Infections. In Clinical Infectious Disease: A practical approach, Root, K. (ed). P: 649-656. Oxford University Press, Inc, New York.
37-Takeuchi H, Yamamoto S, Terai A, Kurazono H, Takeda Y, Okada Y, Yoshida O. Detection of Proteus mirabilis urease gene in urinary calculi by polymerase chain reaction International journal of Urology, Vol. 3(3), (1996);pp:202-206 .
38-Thaler ER, Kennedy DW (2000). Cited in human, H.D.; Dupont, H.L.; Gradner, L.B. and Griffin, J.W. Textbook of internal medicine.4th ed. Wolters Kluwer Company, USA.
39-Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 35(Web Server issue), (2007); pp: 71-74.
40-Uphoff TS, Welch RA. Nucleotide sequencing of the *proteus mirabilis* calcium-independent hemolysin genes (hpmA and hpmB) reveals sequence similarity with the *serratia marcescens* hemolysin genes (shlA and shlB). J. of bacterial. , Vol.173 (3), (1990); pp: 1206-1216.

41-Winokur PL, Canton R, Casellas J-M, Legakis N. Variations in the performance of strains expressing an extended-spectrum β-Lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clinical Infections Diseases. Vol.32 (2), (2001); pp: 94-103.